文摘
摘要目的:评估早期治疗之间的关系和风险的复发缓和多发性硬化患者的残疾退休金(名RRMS)。
背景:疾病修饰治疗的早期启动(DMT)已经显示出有益的名RRMS患者对临床结果的影响,但对社会经济影响的结果仍然不清楚。
设计/方法:使用全国丹麦多发性硬化症注册表,我们包括患者一个名RRMS从1开始。1996年1月为1。2016年1月。四年后发病,患者分类根据他们的第一次治疗开始:1年内发病(早期),1 - 4年(中间)和从4到8年(晚)。社会经济数据参数获得的全国连锁,以人群为基础的注册中心。我们评估了DMT的时间之间的联系开始,使用Cox回归残疾退休金。
结果:队列由1922年5208例早期的初学者来说,2126中间初学者和1160起步晚。年龄和性别被均匀地分布在所有组,平均年龄:37 (SD:±9)年,男女比例:1:2。意味着eds基线略有不同:早期:1.5 (SD:±1),中级:1.7 (SD:±1)和晚期:1.9 (SD:±1)。基线水平的教育和同居状态相似,但接受财政支持的病人的比例不同:早期34%,中间29%和14%。相比早期的发起者,接收残疾退休金从发病开始随着时间的增加而增加的DMT:中级:人力资源1.33(95%置信区间:1.09—-1.63)和晚期:人力资源1.88(95%置信区间:1.48—-2.39)。进一步的风险接受残疾退休金与增加eds,慢性并发症和贫困劳动力市场关系的存在。
结论:早期治疗可能推迟时间残疾退休金。我们的发现支持指南重点是早期治疗起始,强调早期诊断的重要性。
披露:Wandall-Holm先生没有披露。马赛厄斯Buron没有披露。齿Iskov科普已收到个人薪酬在500 - 4999美元的范围与生原体作为国会参与费。Sellebjerg博士已经收到个人赔偿作为丹麦多发性硬化症协会的一名雇员。Sellebjerg博士已经收到个人薪酬在10000 - 49999美元的范围为诺华公司担任顾问。Sellebjerg博士已经收到个人薪酬在5000 - 9999美元的范围为在科学咨询服务或数据安全监测委员会生原体。Sellebjerg博士已经收到个人薪酬在5000 - 9999美元的范围为在科学咨询服务或数据安全监测委员会诺华。Sellebjerg博士已经收到个人薪酬在5000 - 9999美元的范围为在科学咨询服务或数据安全监测委员会罗氏。Sellebjerg博士已经收到个人薪酬在5000 - 9999美元的范围为在科学咨询服务或为赛诺菲Genzyme数据安全监测委员会。Sellebjerg博士已经收到个人薪酬在500 - 4999美元的范围在生原体的演讲人。 Dr. Sellebjerg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Sellebjerg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Sellebjerg has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Gangsted Foundation. Dr. Sellebjerg has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Warwara Larsen Foundation. The institution of Dr. Sellebjerg has received research support from Biogen. The institution of Dr. Sellebjerg has received research support from Merck. The institution of Dr. Sellebjerg has received research support from Novartis. The institution of Dr. Sellebjerg has received research support from Sanofi Genzyme. Dr. Sellebjerg has received publishing royalties from a publication relating to health care. Dr. Magyari has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Magyari has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Magyari has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Magyari has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Magyari has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Dr. Magyari has received research support from The Danish MS Society. The institution of Dr. Magyari has received research support from Biogen. The institution of Dr. Magyari has received research support from Novartis. The institution of Dr. Magyari has received research support from Roche. The institution of Dr. Magyari has received research support from Merck. The institution of Dr. Magyari has received research support from Sanofi.
